Delivery Order SPE2DB22D2007-SPE2DB24FJ1HV
Award Date 4/8/24
Potential Completion Date 4/9/24
Potential Value $40K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of XIFAXAN 550 mg tablets. The order, valued at $5,473.81, has an ultimate completion date of April 8, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply the pharmaceutical product XIFAXAN 550 mg tablets. The contract has a ceiling value of $82,211.95 and an ultimate completion date of March 21, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31,...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide XIFAXAN 550 mg tablets. The order has a completion date of February 29, 2024 and a potential value of $141,111.04. AmerisourceBergen Drug Corp also holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, to deliver a comprehensive range of pharmaceutical products and medical...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $6,122.56 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide XIFAXAN 550 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary vehicle for...
- The Defense Logistics Agency awarded a $6,855.80 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of XIFAXAN 550 MG TABLET UD 60S. This delivery order contract has a completion date of February 27, 2024. Amerisourcebergen Drug Corp is the prime contractor and no set-aside designation was used. The delivery order is issued under an indefinite delivery contract with a potential value of $999,999,999.00 and a...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The contract, valued at $2,040.98, is for the delivery of XIFAXAN 550 mg tablets to support military treatment programs and facilities. This delivery order falls under a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract for $20,387.23 to supply XIFAXAN 550 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded by DLA to Amerisourcebergen Drug Corp, which serves as the primary vehicle for the company to provide pharmaceutical products and medical supplies to DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to supply XIFAXAN 550 MG TABLET 60S to support military treatment programs and facilities. The contract, valued at $10,960.48, has an ultimate completion date of April 3, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA with a potential value of $999,999,999.00 and a performance period...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,777.98 Firm Fixed Price Delivery Order contract to Amerisourcebergen Drug Corp for the supply of XIFAXAN 550 MG TABLET 60S. This contract, which has a completion date of September 18, 2024, is not a set-aside award. Amerisourcebergen, a major pharmaceutical distributor, has been awarded numerous federal contracts and Indefinite Delivery Contracts (IDCs) by various defense and civilian agencies, including the DLA Troop Support Medical and the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation, is a delivery order valued at $3,555.96. The order was placed by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense, to supply XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of April 2, 2024. This delivery order is part of a...